Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Kaposi 3Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Acquired Immunodeficiency Syndrome 2Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Epstein-Barr Virus Infections 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

Temozolomide 5O(6)-benzylguanine 3Vorinostat 2Radiotherapy 2Oxaliplatin 2Lenalidomide 2Cilengitide 2Carboplatin 2veliparib 1tipifarnib 1romidepsin 1pomalidomide 1pazopanib 1ixabepilone 1ispinesib 1cediranib 1becatecarin 1alvocidib 1Verteporfin 1Tamoxifen 1RMP 7 1PT-100 dipeptide 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gelclair 1Filgrastim 1Erlotinib Hydrochloride 1Doxorubicin 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Optic Nerve Glioma × pomalidomide × Clear all
NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
CNS

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡